Investing considerably in production capacity for medical device packaging at its Rohrdorf and Halle sites in Germany
Lupin updates on shipment of Mirabegron ER Tablets
Receives 3 final and 2 tentative product approvals thus far in Q1FY25
the campaign emphasizes the brand's reliability and effectiveness in providing timely relief
The product is used to treat amyotrophic lateral sclerosis
First BTK inhibitor to show favourable trend in overall survival vs. standard-of-care chemoimmunotherapy in this setting
The Unit currently caters to emerging markets of Latin America and Africa with a variety of dosage forms
With this, for all our USFDA facilities, EIRs are in place
The brand has also unveiled a new TVC campaign in Telangana and Andhra Pradesh to drive brand awareness
Subscribe To Our Newsletter & Stay Updated